Recherches "plusieurs pathologies" AcSé Nivolumab Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types Paris
Phases précoces tumeurs solides CA009-002 (Immuno) A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy;of anti-GITR Monoclonal Antibody (BMS-986156) Administered Alone and in Combination;with Nivolumab (BMS-936558, anti PD-1 Monoclonal Antibody) in Advanced Solid Tumors Paris EMANUELA ROMANO
Phases précoces tumeurs solides CA017-003 A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) and in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors. Paris CHRISTOPHE LE TOURNEAU
Phases précoces tumeurs solides CPDR001X2103 Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib). Paris
Phases précoces tumeurs solides DRIIV-1 (OX2016 -203-01) An open-label, dose-escalation phase I study to assess the safety, pharmacokinetics and pharmacodynamics of AsiDNA, a DNA repair inhibitor administered intravenously in patients with advanced solid tumors. Paris CHRISTOPHE LE TOURNEAU
Sarcomes EORTC-1447- STBSG Maintenance Therapy With Trabectedin Versus Observation After First Line Treatment With Doxorubicin of Patients With Advanced or Metastatic Soft Tissue Sarcoma. Paris SOPHIE PIPERNO-NEUMANN
Phases précoces tumeurs solides M15-819 A Multi-Center, Phase 1, Open-Label, Dose-Escalation Study of ABBV-428, an Immunotherapy in Subjects With Advanced Solid Tumors. Paris CHRISTOPHE LE TOURNEAU
Recherches "plusieurs pathologies" SHIVA02 (IC 2016-06) Evaluation of the Efficacy of Targeted Therapy Based on Tumor Molecular Profiling in Patients With Advanced Cancer Using Each Patient as Its Own Control. Paris, Saint-Cloud CHRISTOPHE LE TOURNEAU
Phases précoces tumeurs solides GO30103 (TIGIT) A Phase Ia/Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors. Paris EMANUELA ROMANO
Recherches "plusieurs pathologies" CHECK'UP Prospective Cohort Study to Identify the Predictive Factors of Response to PD-1 or PD-L1 Antagonists. Paris